Skip to content

EYPT

EyePoint Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$12.66-4.81%

Price as of Jul 20, 2026

EYPT news

EyePoint Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3

    Globe Newswire ·

  2. EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNXb1Qmgs&default-theme=true WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. E

    Globe Newswire ·